Search Tag: Landiolol

ICU Management

Management of Acute Arrhythmias in Patients With Cardiac Dysfunction - Update of ESC Guidelines

2021 30 Sep

In 2020, the ultra-short acting beta-blocker landiolol was first included in the ESC guidelines with a class I recommendation. The recommendations were based on study results demonstrating the rapid response, efficacy, and safety of this drug. At a recent symposium, during 2021 Heart Failure World Congress, cardiologists were invited to present... Read more

ICU Management

Evidence-Based Management of Atrial Fibrillation

2021 22 Feb

The 2020 ESC Guidelines and the addition of Landiolol An overview of the updated guidelines for the diagnosis and management of atrial fibrillation, developed in association with the European Association for Cardio-Thoracic Surgery. T he European Society of Cardiology (ESC) provides a range of scientific and educational activities,... Read more

ICU Management

Atrial Fibrillation and Sepsis: A Life-Threatening Combination

2020 08 Oct

Almost half of the patients with sepsis suffer from myocardial depression and a reduced ejection fraction. Sepsis can also cause changes in circulating volume, vascular tone, and coronary blood flow, all of which affect heart function and heart rate. Serum catecholamine levels and direct measurements of renal sympathetic nerve activity have shown that... Read more

ICU Management

COVID-19 and the Potential Effects on the Cardiovascular System

2020 11 Aug

COVID-19 affects the myocardium and myocarditis and cardiac injury is a common condition among hospitalised patients. Landiolol, a new ultra-short acting, intravenous most  β 1 selective blocker, can help reduce inflammation and provide therapeutic benefits. Influenza, bacterial pneumonias, respiratory infections and viruses... Read more